Rigel to Present at the Jefferies Global Healthcare Conference in London
Rigel Pharmaceuticals: Top-Line Momentum Meets Margin Compression In Q3
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $86
Rigel Pharmaceuticals Q3 Earnings Call Highlights
Rigel Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $47
Rigel (RIGL) Q3 2026 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings Estimates
Rigel: Q3 Earnings Snapshot
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
Rigel Reports Third Quarter 2026 Financial Results
Rigel Pharmaceuticals Q3 2026 Earnings Call Transcript
Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $285.000M-$295.000M to $290.000M-$295.000M vs $305.733M Est
Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
Rigel Pharmaceuticals Shares Rose Even As Profit Fell
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.